Histone modifying enzymes as targets for therapeutic intervention in oesophageal adenocarcinoma
Histone modifying enzymes as targets for therapeutic intervention in oesophageal adenocarcinoma
Oesophageal adenocarcinoma (OAC) has a dismal prognosis, where curable disease occurs in less than 40% of patients, and many of those with incurable disease survive for less than a year from diagnosis. Despite the widespread use of systematic chemotherapy in OAC treatment, many patients receive no benefit. New treatments are urgently needed for OAC patients. There is an emerging interest in epigenetic regulators in cancer pathogenesis, which are now translating into novel cancer therapeutic strategies. Histone-modifying enzymes (HMEs) are key epigenetic regulators responsible for dynamic covalent histone modifications that play roles in both normal and dysregulated cellular processes including tumorigenesis. Several HME inhibitors are in clinical use for haematological malignancies and sarcomas, with numerous on-going clinical trials for their use in solid tumours. This review discusses the current literature surrounding HMEs in OAC pathogenesis and their potential use in targeted therapies for this disease.
Biomarker, EZH2, Epigenetics, HDAC, Histone modifying enzymes, Oesophageal cancer
Pickering, Oliver J
be6ea105-6204-41ac-88e7-9ca813ce03b5
Breininger, Stella P
b6027df8-22a3-4d09-8799-6d14123f9ce4
Underwood, Timothy J
8e81bf60-edd2-4b0e-8324-3068c95ea1c6
Walters, Zoë S
e1ccd35d-63a9-4951-a5da-59122193740d
13 August 2021
Pickering, Oliver J
be6ea105-6204-41ac-88e7-9ca813ce03b5
Breininger, Stella P
b6027df8-22a3-4d09-8799-6d14123f9ce4
Underwood, Timothy J
8e81bf60-edd2-4b0e-8324-3068c95ea1c6
Walters, Zoë S
e1ccd35d-63a9-4951-a5da-59122193740d
Pickering, Oliver J, Breininger, Stella P, Underwood, Timothy J and Walters, Zoë S
(2021)
Histone modifying enzymes as targets for therapeutic intervention in oesophageal adenocarcinoma.
Cancers, 13 (16), [4084].
(doi:10.3390/cancers13164084).
Abstract
Oesophageal adenocarcinoma (OAC) has a dismal prognosis, where curable disease occurs in less than 40% of patients, and many of those with incurable disease survive for less than a year from diagnosis. Despite the widespread use of systematic chemotherapy in OAC treatment, many patients receive no benefit. New treatments are urgently needed for OAC patients. There is an emerging interest in epigenetic regulators in cancer pathogenesis, which are now translating into novel cancer therapeutic strategies. Histone-modifying enzymes (HMEs) are key epigenetic regulators responsible for dynamic covalent histone modifications that play roles in both normal and dysregulated cellular processes including tumorigenesis. Several HME inhibitors are in clinical use for haematological malignancies and sarcomas, with numerous on-going clinical trials for their use in solid tumours. This review discusses the current literature surrounding HMEs in OAC pathogenesis and their potential use in targeted therapies for this disease.
Text
cancers-13-04084-v2
- Version of Record
More information
Accepted/In Press date: 10 August 2021
e-pub ahead of print date: 13 August 2021
Published date: 13 August 2021
Additional Information:
Funding Information:
Funding: This research was funded by Cancer Research UK & Royal College of Surgeons of England Advanced Clinician Scientist Fellowship to T.J.U. “Cellular interplay in oesophageal cancer.” A23924.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Keywords:
Biomarker, EZH2, Epigenetics, HDAC, Histone modifying enzymes, Oesophageal cancer
Identifiers
Local EPrints ID: 451523
URI: http://eprints.soton.ac.uk/id/eprint/451523
ISSN: 2072-6694
PURE UUID: 0539bd02-24ec-496c-9f64-3bfc448d1a69
Catalogue record
Date deposited: 05 Oct 2021 19:21
Last modified: 17 Mar 2024 03:48
Export record
Altmetrics
Contributors
Author:
Oliver J Pickering
Author:
Stella P Breininger
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
